Darling Ingredients Inc. has achieved a significant milestone in the health and nutrition sector as its leading health brand, Rousselot, received a new U.S. patent for Nextida GC, an innovative collagen peptide ingredient designed to support healthy post-meal blood glucose levels. The patent grant further strengthens the company’s growing portfolio of science-based nutritional solutions aimed at addressing some of the most pressing health concerns facing consumers worldwide.
The United States Patent and Trademark Office (USPTO) has officially awarded Patent No. US12636339 for Nextida GC, recognizing both the proprietary manufacturing process behind the ingredient and its application as a dietary supplement ingredient. The patent provides intellectual property protection for a product that offers consumers a natural, non-pharmaceutical approach to supporting blood sugar management through targeted nutrition.
The announcement highlights Darling Ingredients’ commitment to advancing collagen science beyond traditional applications such as beauty, joint health, and sports nutrition. Through Rousselot, the company is increasingly focusing on developing specialized collagen peptide solutions that address specific functional health needs and emerging wellness trends.
Addressing a Growing Global Health Concern
Maintaining healthy blood glucose levels has become a major focus for healthcare professionals and consumers alike. Rising rates of metabolic disorders, prediabetes, and type 2 diabetes have increased interest in preventative health measures and nutritional interventions that can help individuals better manage their metabolic health.
Many consumers are seeking alternatives that complement traditional healthcare approaches, particularly solutions that can be incorporated into everyday wellness routines. This shift has created growing demand for functional ingredients backed by scientific research and clinical evidence.
Nextida GC was developed specifically to address this need. The collagen peptide composition is formulated to support healthy glucose metabolism and help manage blood sugar responses following meals. By offering a nutritional solution rather than a pharmaceutical intervention, the ingredient aligns with the broader consumer trend toward natural health products and preventative wellness strategies.
The newly awarded patent underscores the uniqueness of the technology and reinforces the scientific foundation supporting the ingredient’s development.
Strengthening Leadership in Collagen Innovation
Darling Ingredients Chairman and Chief Executive Officer Randall C. Stuewe emphasized the strategic importance of the patent award and its role in supporting the company’s long-term innovation objectives.
According to Stuewe, the patent validates the scientific research behind Nextida GC while demonstrating the company’s ability to leverage decades of collagen expertise to create targeted health solutions. He noted that consumer interest in natural approaches to health and wellness continues to accelerate, creating opportunities for innovative ingredients that address specific health concerns.
The CEO also highlighted the company’s broader vision for expanding its Nextida product platform. As demand grows for evidence-based nutritional ingredients, Darling Ingredients aims to strengthen its leadership position within the collagen peptide sector while building a diversified pipeline of specialized health solutions.
The patent achievement reflects a broader strategy focused on developing functional ingredients that move beyond traditional collagen applications. Instead of serving solely as structural protein supplements, next-generation collagen peptides are increasingly being designed to provide targeted physiological benefits.
Expanding the Nextida Portfolio
Nextida GC represents one component of Rousselot’s growing Nextida family of collagen peptide ingredients. The product portfolio is being developed to address a range of health and wellness categories through scientifically validated formulations.
Collagen peptides have become one of the fastest-growing ingredient categories within the global nutritional supplement market. Their versatility allows them to be incorporated into capsules, powders, beverages, functional foods, and other dietary supplement formats.
With Nextida GC, Rousselot is extending collagen technology into the metabolic health segment, a market that continues to experience significant growth due to increasing consumer awareness of blood sugar management and overall metabolic wellness.
Industry analysts view personalized and targeted nutrition as a major growth driver for the health ingredient sector. Products designed to address specific health outcomes are increasingly preferred by consumers seeking measurable benefits and science-backed solutions.
The patent protection for Nextida GC positions Rousselot to capitalize on these trends while providing manufacturers with access to a differentiated ingredient supported by proprietary technology.
Growing International Recognition
The U.S. patent is not the only intellectual property success achieved by Rousselot for Nextida GC. The ingredient has already received patent protection in several major international markets, demonstrating global recognition of its innovation and uniqueness.
Patent authorities in Australia, Europe, Japan, and China have each granted protection for the ingredient. These approvals further strengthen Rousselot’s intellectual property portfolio and support the commercialization of Nextida GC across key global regions.
The company has secured the following patents:
- Australia: Patent AU2023279850B2
- Europe: Patent EP4498839B1
- Japan: Patent JP7751755B2
- China: Patent CN119212574B
In addition to these granted patents, patent applications remain under review in several other important markets, including Brazil, Canada, Colombia, South Korea, Mexico, India, and Peru.
This expanding international patent coverage provides Rousselot with a strong foundation for future growth and market expansion. It also demonstrates confidence among global patent offices regarding the novelty and scientific significance of the technology.
Meeting Future Consumer Demand
The health and wellness industry continues to evolve as consumers become more proactive about managing long-term health outcomes through nutrition and lifestyle choices. Functional ingredients that support metabolic health, healthy aging, immunity, and overall wellness are expected to remain key growth categories in the coming years.
As part of Darling Ingredients’ broader innovation strategy, Rousselot is positioning itself to meet these evolving consumer demands through research-driven ingredient development. The success of Nextida GC highlights how advances in collagen science can create new opportunities within the nutritional supplement market.
By securing patent protection for both the production process and application of Nextida GC, Darling Ingredients has strengthened its competitive position while providing the industry with a novel ingredient solution designed to support healthy blood glucose regulation naturally.
The latest patent milestone not only validates years of research and development but also reinforces Rousselot’s role as a leader in collagen peptide innovation. As the company continues expanding its portfolio of targeted health ingredients, Nextida GC represents an important step toward delivering science-backed nutritional solutions that address some of the most significant health challenges facing consumers around the world.
Source Link:https://www.businesswire.com/
